Skip to main content

Table 1 Overview of the 33 TCGA studies used in this analysis

From: Identification and ranking of recurrent neo-epitopes in cancer

Project name

Number of patients

Variants per patients

Missense variant per patient

Recurrent variants

Strong binders

 

Total

With clinical data

Average

Median

Average

Median

  

TCGA-BLCA

412

412

326

226

157

109

22

14

TCGA-BRCA

986

986

123

62

50

25

8

10

TCGA-CESC

289

289

358

157

143

62

17

16

TCGA-COAD

399

397

666

176

288

82

41

34

TCGA-ESCA

184

184

246

187

95

73

80

72

TCGA-GBM

393

390

212

70

93

36

15

5

TCGA-HNSC

508

508

201

139

97

66

14

3

TCGA-KIRC

336

336

79

69

33

31

0

0

TCGA-KIRP

281

281

85

82

39

38

5

2

TCGA-LAML

143

143

69

15

16

6

14

7

TCGA-LGG

508

507

70

36

33

16

14

0

TCGA-LIHC

364

364

149

120

70

58

11

16

TCGA-LUAD

567

515

367

242

180

113

7

0

TCGA-LUSC

492

492

368

301

187

153

20

19

TCGA-OV

436

435

173

121

58

47

10

7

TCGA-PAAD

178

178

168

50

77

19

24

12

TCGA-PCPG

179

179

13

12

5

4

8

5

TCGA-PRAD

495

495

59

35

27

15

3

7

TCGA-READ

137

136

475

148

232

70

320

186

TCGA-SARC

237

237

119

70

45

26

2

0

TCGA-SKCM

467

467

841

472

413

229

266

220

TCGA-STAD

437

437

488

157

211

74

17

14

TCGA-TGCT

144

128

23

21

9

8

9

6

TCGA-THCA

492

492

22

12

6

5

4

3

TCGA-THYM

123

123

39

24

10

4

6

2

TCGA-UCEC

530

530

1672

149

708

54

118

109

TCGA-ACC

92

92

117

36

0

0

0

0

TCGA-CHOL

51

45

110

62

0

0

0

0

TCGA-DLBC

37

37

173

157

0

0

0

0

TCGA-KICH

66

66

44

25

0

0

0

0

TCGA-MESO

82

82

47

44

0

0

0

0

TCGA-UCS

57

57

183

67

0

0

0

0

TCGA-UVM

80

80

23

16

0

0

0

0

Total

10182

10100

Total number: 3155183

Total number: 1384531

1055

769

  1. The 7 studies displayed at the bottom have not been used for the determination of recurrent vairants, as the number of patients is less than 100. The number of strong binders includes all occurrences of neo-epitopes candidates, so a candidate may be counted multiple times when it is predicted to be binding several HLA-1 types